drugset / Trial / NCT06649747

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

NCT06649747 ↗

Phase 2 Not yet recruiting 408 enrolled Afasci Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to evaluate if the drug candidate AFA-281 works to treat chronic low back and leg pain caused by painful lumbosacral radiculopathy (PLSR) in adults. This trial will also evaluate the safety of AFA-281. The main questions it aims to answer are: * Does AFA-281 mitigate pain? * What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 works to treat chronic low back and leg pain. Participants will: * Take drug AFA-281 or a placebo three times every day for 4 weeks * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their pain scores and about mood and sleep questionnaires, and the number of times they use a rescue pain medicines.

Timeline

Start
2027-04-01
Primary completion
2032-03-31
Completion
2032-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator AFA-281 Small molecule 60 mg Oral
Comparator AFA-281 Small molecule 120 mg Oral
Comparator AFA-281 Small molecule 240 mg Oral

Indications